Use of defibrinating agents ancrod and reptilase in the treatment of thromboembolism.
D000743:Anemia, Hemolytic / Q000139:chemically induced; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001779:Blood Coagulation Factors; D001792:Blood Platelets / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects; D004351:Drug Resistance; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006868:Hydrolysis; D007457:Iodine Radioisotopes; D010447:Peptide Hydrolases / Q000627:therapeutic use*; D010958:Plasminogen / Q000032:analysis; D011247:Pregnancy; D012910:Snake Venoms; D013917:Thrombin; D013923:Thromboembolism / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology; D014945:Wound Healing / Q000187:drug effects
D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents; D007457:Iodine Radioisotopes; D012910:Snake Venoms; D005337:Fibrin; D005340:Fibrinogen; D010958:Plasminogen; D006493:Heparin; D010447:Peptide Hydrolases; D013917:Thrombin; D014568:Urokinase-Type Plasminogen Activator